The pharma said Thursday it is stopping a late-stage study of its blockbuster Keytruda, anti-TIGIT antibody vibostolimab and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer, following a recommendation from an independent data monitoring committee.
